GFAP and myeloid sarcoma: We performed a semi-quantification analysis of specific markers of gliosis (S100B+ and GFAP+) and demyelination (sum of the MBP-negative areas) on C1–C4 cervical spinal cord segments, where neuropathological biomarkers are known to be especially apparent in this MS animal model (for review, see [20]), comparing EAE mice treated with the vehicle or AA.